Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group Study

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 262-266

  Sledge Jr , George W ^a   Hu, P ^a   Falkson, G ^a   Tormey, D ^a   Abeloff, M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DIETHYLSTILBESTROL; DOXORUBICIN; FLUOROURACIL; FLUOXYMESTERONE; MEDROXYPROGESTERONE; METHOTREXATE; NORETHISTERONE ACETATE; PREDNISONE; TAMOXIFEN; TIOGUANINE; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HORMONE SENSITIVITY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0342514500     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.262     Document Type: Article

References (15)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45:8-30, 1995
2. Falkson G, Gelman R, Pandya K, et al: Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16:1669-1676, 1998
3. Metha C, Patel N: A network algorithm for performing Fisher's exact test in r times c contingency tables. J Am Stat Assoc 78:427-434, 1983
4. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
5. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J Royal Stat Soc 135:185-206, 1972
6. Group AaNZBCT: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4:186-193, 1986
7. Mouridsen HT, Rose C, Engelsman E, et al: Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer: A randomized study of CMF vs CMF plus tamoxifen. Eur J Cancer Clin Oncol 21:291-299, 1985
8. Perry MC, Kardinal CG, Korzun AH, et al: Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B Protocol 8081. J Clin Oncol 5:1534-1545, 1987
9. Krook JE, Ingle JN, Green SJ, et al: Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. Cancer Treat Rep 69:355-361, 1985
10. Viladiu P, Alonso MC, Avella A, et al: Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients: A randomized trial. Cancer 56:2745-2750, 1985
11. Cocconi G, De Lisi V, Boni C, et al: Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: A prospective randomized study. Cancer 51:581-588, 1983
12. Rubens RD, Begent RHJ, Knight RK, et al: Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer 42:1680-1686, 1978
13. Tormey DC, Falkson G, Crowley J, et al: Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. Am J Clin Oncol 5:33-39, 1982
14. Brunner KW, Sonntag RW, Alberto P, et al: Combined chemoand hormonal therapy in advanced breast cancer. Cancer 39:2923-2933, 1977
15. Kardinal CG, Pedrry MC, Korzun AH, et al: Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy: A subset analysis of CALGB study 8081. Cancer 61:415-419, 1988